{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Cervical+Squamous+Cell+Carcinoma&page=5", "query": { "condition": "Advanced Cervical Squamous Cell Carcinoma", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 664, "total_pages": 67, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Cervical+Squamous+Cell+Carcinoma&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Cervical+Squamous+Cell+Carcinoma&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T01:25:27.366Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04504669", "title": "First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clear Cell Renal Cell Cancer", "Non-Small-Cell Lung Cancer", "Triple Negative Breast Neoplasms", "Squamous Cell Cancer of Head and Neck", "Small Cell Lung Cancer", "Gastroesophageal Cancer", "Melanoma", "Cervical Cancer", "Advanced Solid Tumours" ], "interventions": [ { "name": "AZD8701", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "18 Years to 101 Years" }, "enrollment_count": 60, "start_date": "2020-08-18", "completion_date": "2024-10-07", "has_results": false, "last_update_posted_date": "2024-11-05", "last_synced_at": "2026-10-11T01:25:27.366Z", "location_count": 6, "location_summary": "Baltimore, Maryland • St Louis, Missouri • Huntersville, North Carolina + 3 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Franklin", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04504669" }, { "nct_id": "NCT00003864", "title": "Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "1999-09-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2023-06-15", "last_synced_at": "2026-10-11T01:25:27.366Z", "location_count": 71, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 52 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003864" }, { "nct_id": "NCT03277352", "title": "INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignancies", "Metastatic Cancer" ], "interventions": [ { "name": "INCAGN01876", "type": "DRUG" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2017-11-21", "completion_date": "2020-07-01", "has_results": true, "last_update_posted_date": "2021-07-22", "last_synced_at": "2026-10-11T01:25:27.366Z", "location_count": 2, "location_summary": "Los Angeles, California • Hackensack, New Jersey", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03277352" }, { "nct_id": "NCT00093652", "title": "Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "gefitinib", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2003-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-10-06", "last_synced_at": "2026-10-11T01:25:27.366Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00093652" }, { "nct_id": "NCT05050162", "title": "Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced Head and Neck Squamous Cell Carcinoma", "Advanced Hypopharyngeal Squamous Cell Carcinoma", "Advanced Laryngeal Squamous Cell Carcinoma", "Advanced Oropharyngeal Squamous Cell Carcinoma", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1714, "start_date": "2022-02-01", "completion_date": "2027-02-09", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-11T01:25:27.366Z", "location_count": 361, "location_summary": "Mobile, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 264 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Antioch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05050162" }, { "nct_id": "NCT02644122", "title": "SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma" ], "interventions": [ { "name": "SF1126", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ezra Cohen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2016-11", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2018-07-11", "last_synced_at": "2026-10-11T01:25:27.366Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02644122" }, { "nct_id": "NCT01716195", "title": "Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Induction Chemotherapy followed by Response Adapted Chemoradiation", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2012-10", "completion_date": "2020-10-01", "has_results": true, "last_update_posted_date": "2021-02-26", "last_synced_at": "2026-10-11T01:25:27.366Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01716195" }, { "nct_id": "NCT02636036", "title": "Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Epithelial Tumor" ], "interventions": [ { "name": "enadenotucirev", "type": "BIOLOGICAL" }, { "name": "nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Akamis Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2016-01-25", "completion_date": "2021-10-08", "has_results": false, "last_update_posted_date": "2021-11-09", "last_synced_at": "2026-10-11T01:25:27.366Z", "location_count": 6, "location_summary": "Tucson, Arizona • Duarte, California • Santa Monica, California + 3 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02636036" }, { "nct_id": "NCT04370587", "title": "A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Melanoma", "HNSCC", "Sarcoma", "Squamous Cell Carcinoma", "NSCLC" ], "interventions": [ { "name": "T3011", "type": "BIOLOGICAL" }, { "name": "T3011 + pembrolizumab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "BIOLOGICAL", "COMBINATION_PRODUCT" ], "sponsor": "ImmVira Pharma Co. Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-09-17", "completion_date": "2027-01-10", "has_results": false, "last_update_posted_date": "2025-10-08", "last_synced_at": "2026-10-11T01:25:27.366Z", "location_count": 6, "location_summary": "Gilbert, Arizona • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04370587" }, { "nct_id": "NCT01334177", "title": "TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Salivary Gland Squamous Cell Carcinoma", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IV Salivary Gland Cancer", "Stage IVA Squamous Cell Carcinoma of the Larynx", "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Verrucous Carcinoma of the Larynx", "Stage IVA Verrucous Carcinoma of the Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Verrucous Carcinoma of the Larynx", "Stage IVB Verrucous Carcinoma of the Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Larynx", "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Oropharynx", "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Verrucous Carcinoma of the Larynx", "Stage IVC Verrucous Carcinoma of the Oral Cavity", "Tongue Cancer" ], "interventions": [ { "name": "TLR8 agonist VTX-2337", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacogenomic studies", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2011-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-03-05", "last_synced_at": "2026-10-11T01:25:27.366Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01334177" } ] }